What is Zacks Research’s Estimate for BHC Q2 Earnings?

Bausch Health Companies Inc. (NYSE:BHC) – Analysts at Zacks Research upped their Q2 2025 earnings per share estimates for Bausch Health Companies in a note issued to investors on Tuesday, December 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.03 for the quarter, up from their previous forecast of $1.00. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies’ FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.09 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.37 EPS and FY2026 earnings at $5.05 EPS.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. The company had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. Bausch Health Companies’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.03 EPS.

A number of other equities analysts also recently issued reports on BHC. Evercore ISI raised Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Royal Bank of Canada upped their price objective on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. Finally, StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.75.

Bausch Health Companies Stock Down 4.4 %

NYSE BHC opened at $7.34 on Thursday. The stock has a market capitalization of $2.65 billion, a P/E ratio of -15.29 and a beta of 0.69. Bausch Health Companies has a 52-week low of $3.96 and a 52-week high of $11.46. The firm has a 50-day moving average price of $8.37 and a 200 day moving average price of $7.27.

Institutional Investors Weigh In On Bausch Health Companies

Institutional investors and hedge funds have recently modified their holdings of the company. Mackenzie Financial Corp boosted its position in Bausch Health Companies by 111.0% during the second quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after purchasing an additional 1,252,834 shares in the last quarter. LMR Partners LLP acquired a new position in shares of Bausch Health Companies during the 3rd quarter worth $3,264,000. Clearline Capital LP purchased a new stake in shares of Bausch Health Companies in the 2nd quarter worth about $6,881,000. Intact Investment Management Inc. acquired a new stake in Bausch Health Companies in the 3rd quarter valued at about $1,543,000. Finally, XTX Topco Ltd purchased a new position in Bausch Health Companies during the 3rd quarter valued at about $938,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.